Thyroid Disorders: Graves' Disease and Multinodular Goiter

Pathophysiology and Clinical Presentation

• Multinodular goiter results from abnormal growth and enlargement of the thyroid gland with nodule formation, typically developing over many years, and is more common in women in their fifth and sixth decades, according to the American College of Radiology 1
• When toxic, multinodular goiter represents autonomous hyperfunctioning nodules rather than autoimmune stimulation, as stated by the American College of Radiology 1 and Praxis Medical Insights 2
• Multinodular goiter can present with obstructive symptoms, such as dyspnea, orthopnea, dysphagia, or dysphonia, and can be euthyroid or hyperthyroid, as noted by the American College of Radiology 1 and Praxis Medical Insights 2
• The American College of Radiology recommends that multinodular goiter be diagnosed based on nodular thyroid enlargement that can be asymmetric or involve one lobe predominantly 1

Diagnostic Approach

• The American College of Radiology and Praxis Medical Insights recommend starting with TSH measurement before any imaging, and using thyroid ultrasound as first-line imaging for both conditions when TSH is abnormal [1] [2]
• For Graves' disease diagnosis, positive TSH receptor antibodies (TRAbs) confirm diagnosis, as stated by the Journal of Clinical Oncology 3
• The American College of Radiology and Praxis Medical Insights recommend using radioiodine uptake scan and Doppler ultrasound to diagnose Graves' disease and multinodular goiter [1] [2]

Treatment and Prognosis

• The American College of Radiology recommends observation for asymptomatic non-toxic multinodular goiter, and surgery for obstructive symptoms or cosmetic concerns 1
• Praxis Medical Insights recommends starting with TSH measurement before ordering thyroid imaging, and not relying on prolonged antithyroid drug therapy for toxic multinodular goiter expecting remission 2

Surgical Indications and Outcomes for Thyroidectomy

Indications for Thyroidectomy

• The American College of Radiology recommends surgery for patients with compressive symptoms from goiter, as it directly addresses mechanical obstruction 4
• The American College of Radiology suggests that surgery is indicated for patients with substernal extension, as RAI is less effective and surgery provides definitive decompression 4
• The National Comprehensive Cancer Network recommends referral to high-volume thyroid surgeons, as complication rates are volume-dependent, with surgeons performing >100 thyroidectomies annually having 4.3% complication rates versus 4-fold higher rates for those performing <10 annually 5

Safety Profile and Outcomes

• The National Comprehensive Cancer Network reports that permanent hypocalcemia occurs in 1.1-3% of patients after thyroidectomy 5
• The American College of Radiology states that total thyroidectomy provides immediate, permanent cure with no recurrences, and is now preferred over subtotal thyroidectomy for both Graves' disease and multinodular goiter 6

Safety Monitoring and Management During Propylthiouracil Bridge Therapy for Toxic Multinodular Goiter

Adverse‑Effect Surveillance

• Agranulocytosis vigilance: In adults receiving PTU as short‑term bridge therapy, clinicians should educate patients to report sore throat or fever promptly, obtain a complete blood count, and discontinue PTU immediately if agranulocytosis is suspected. 7
• Serious adverse‑effect profile: PTU therapy is associated with potentially life‑threatening hepatitis, vasculitis, thrombocytopenia, and severe liver failure that may require transplantation or result in death. 7

Thyroid Hormone Monitoring

• Laboratory follow‑up frequency: Free T4 (or free thyroxine index) should be measured every 2–4 weeks while titrating PTU dose to achieve euthyroidism. 7
• Therapeutic target: The goal is to keep free T4 in the high‑normal range using the lowest PTU dose that maintains control, thereby minimizing drug exposure. 7

Symptom Control

• Adjunctive beta‑blockade: Beta‑blockers such as propranolol or atenolol may be added to alleviate adrenergic symptoms (e.g., tremor, palpitations) until PTU reduces circulating thyroid hormone levels. [7][8]

Epidemiology and Clinical Impact of Hyperthyroidism

Causes of Hyperthyroidism

• Graves' disease accounts for approximately 95 % of hyperthyroidism cases during pregnancy and has a global prevalence of about 2 % among women. This reflects its status as the predominant etiology of thyroid overproduction in this population. 9
• Toxic multinodular goiter, characterized by autonomous hyperfunctioning nodules, is a recognized cause of hyperthyroidism. It contributes to excess thyroid hormone production independent of Graves' disease. 10

Pregnancy‑Related Risks of Untreated Hyperthyroidism

• In pregnant individuals, untreated hyperthyroidism markedly increases the risk of severe preeclampsia, preterm delivery, heart failure, miscarriage, and low birth‑weight infants. Prompt diagnosis and definitive therapy are essential to mitigate these obstetric complications. 9

Morbidity and Mortality in the General Population

• Across the broader adult population, persistent hyperthyroidism is associated with a higher incidence of cardiac arrhythmias, accelerated bone loss leading to osteoporosis, and overall increased mortality. These outcomes underscore the importance of timely definitive treatment. 9, 11

Management of Multinodular Goiter with Substernal Extension and Aberrant Vascular Anatomy

Diagnostic Imaging

• Contrast‑enhanced CT of the neck and mediastinum should be used to document the extent of substernal thyroid tissue and any tracheal displacement; this modality provides the most accurate assessment of mediastinal involvement compared with ultrasound or MRI. 12
• CT is superior to ultrasound and MRI for evaluating the degree of tracheal compression caused by a substernal goiter, making it the preferred first‑line cross‑sectional study in this setting. 13
• Additional cross‑sectional imaging (e.g., repeat CT or MRI) is not required unless fine‑needle aspiration confirms malignancy, thereby avoiding unnecessary radiation exposure and cost. 14

Nodule Risk Stratification

• High‑resolution thyroid ultrasound should be performed to characterize each nodule using ACR TI‑RADS (or an equivalent risk‑stratification system), enabling standardized assessment of malignancy risk across multinodular disease. 12

Aberrant Vascular Anatomy and Surgical Planning

• The presence of a retro‑esophageal right subclavian artery on imaging strongly predicts a non‑recurrent right laryngeal nerve (occurs in <1 % of patients) and markedly increases the risk of nerve injury during thyroidectomy; this anatomic variant should be explicitly communicated to the operating surgeon. 15
• Pre‑operative notification of the surgeon about the aberrant vascular anatomy is mandatory, and baseline flexible laryngoscopy should be obtained to document vocal‑fold mobility before surgery. Detecting pre‑existing vocal‑fold paresis doubles when routine pre‑operative laryngoscopy is performed. 16

All statements are derived from peer‑reviewed evidence published by the American Academy of Otolaryngology–Head and Neck Surgery.

Evidence‑Based Management of Hyperthyroidism with Thyroid Nodules

Laboratory Confirmation of Hyperthyroidism

• In patients with suppressed TSH (< 0.1 mIU/L), measuring free T4 and total T3 (or free T3) within 4 weeks confirms overt hyperthyroidism and reveals that T3‑thyrotoxicosis occurs in approximately 12 % of individuals with autonomous nodules【17】.

• When an initial TSH is low, a repeat TSH measurement is recommended—especially if the value lies between 0.1–0.45 mIU/L—because transient TSH suppression can occur in this range【17】.

Monitoring Strategy for Subclinical Hyperthyroidism

• For patients with TSH 0.1–0.45 mIU/L (subclinical hyperthyroidism), repeat thyroid function testing every 3–12 months until TSH either normalizes or the low level is confirmed stable【17】.

• For patients with TSH < 0.1 mIU/L, repeat testing within 4 weeks, including free T4 and total T3; if hyperthyroidism is confirmed, proceed with a radioiodine uptake scan to determine etiology【17】.

Iodine Exposure in Nodular Thyroid Disease

• Individuals with known nodular thyroid disease are at risk of iodine‑induced overt hyperthyroidism when exposed to excess iodine (e.g., radiographic contrast agents)【17】.